cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.4564921
title: Supplementary Material for: Influences of Various Peptide Linkers on the Thermotoga maritima MSB8 Nitrilase Displayed on the Spore Surface of Bacillus subtilis

description: In the present study, fusion genes composed of <i>Thermotoga maritima</i> MSB8 nitrilase and <i>Bacillus subtilis</i> 168 outer coat protein CotG were constructed with various peptide linkers and displayed on <i>B. subtilis</i> DB 403 spores. The successful display of CotG-nit fusion proteins on the spore surface of <i>B. subtilis</i> was verified by Western blot analysis and activity measurement. It was demonstrated that the fusion with linker GGGGSEAAAKGGGGS presented the highest thermal and pH stability, which is 2.67- and 1.9-fold of the fusion without linker. In addition, fusion with flexible linker (GGGGS)<sub>3</sub> demonstrated better thermal and pH stability than fusions with linkers GGGGS and (GGGGS)<sub>2</sub>. Fusion with rigid linker (EAAAK) demonstrated better thermal stability than fusions with linkers (EAAAK)<sub>2</sub> and (EAAAK)<sub>3</sub>. Fusions with linker (EAAAK)<sub>2</sub> demonstrated better pH stability than fusions with linkers (EAAAK) and (EAAAK)<sub>3</sub>. In the presence of 1 mM dithiothreitol, 1% (v/v) sodium dodecyl sulfate, and 20% (v/v) ethanol, the optimal linkers of the fusions were MGSSSN, GGGGSEAAAKGGGGS, and (GGGGS)<sub>3</sub>, respectively. In summary, our results showed that optimizing the peptide linkers with different type, length, and amino acid composition of the fusion proteins would be an efficient way to maintain the stability of fusion proteins and thus improve the nitrilase display efficiency, which could provide an effective method for rational design peptide linkers of displayed nitrilase on <i>B. subtilis</i>.
DOI: 10.6084/m9.figshare.4564912
title: Supplementary Material for: Initiation and Cessation Timing of Renal Replacement Therapy in Patients with Type 1 Cardiorenal Syndrome: An Observational Study

description: <b><i>Background/Aims:</i></b> Renal replacement therapy (RRT) is a rescue therapy for patients with type 1 cardiorenal syndrome (CRS) with poor prognoses. However, the optimal timing for initiation and cessation of RRT remains controversial. The purpose of this study was to determine the optimal timing of initiation and cessation of RRT for patients with type 1 CRS. <b><i>Methods:</i></b> In this retrospective analysis, patients with refractory type 1 CRS receiving RRT were divided into 3 groups according to weaning from RRT and death within 90 days. Baseline characteristics, underlying heart disease, comorbidities, drug use before RRT, indicators of RRT initiation, and prognosis were compared between the 3 groups. <b><i>Results:</i></b> Fifty-two patients were enrolled, which included 27 males and 25 females with a mean age of 70.7 ± 16.1 years and a 90-day mortality rate of 65.4%. The mean urine output before RRT initiation was 800 mL/ 24 h in the RRT-independent group, 650 mL/24 h in the RRT-dependent group, and 345 mL/ 24 h in the death group (<i>p</i> = 0.021). Additionally, there were obvious differences in fluid balance between the 3 groups (167, 250, and 1,270 mL, respectively, <i>p</i> = 0.016). Patients could be successfully weaned from RRT when urine output was &gt;880 mL and fluid balance volume was &lt;150 mL. <b><i>Conclusion:</i></b> The mean fluid balance of survivors was remarkably less than that of the death group at RRT initiation. RRT termination can be considered when urine output is &gt;880 mL/24 h and volume balance is &lt;150 mL/24 h.
DOI: 10.6084/m9.figshare.4564900
title: Supplementary Material for: Searching the Footprints of Pioneers on Neurology: A Bibliometric Analysis

description: <b><i>Background:</i></b> We identify the most cited articles that have influenced the clinical practices of neurologists. <b><i>Methods:</i></b> We first analyzed the top 100 cited articles published in 50 neurology journals with high impact factors. We collected all of the original articles on clinical neurology published in all 554 medical journals. The Institute for Scientific Information Web of Science search tools were used to identify the top 100 cited articles in the database of Journal Citation Reports since 1950, which were then manually reviewed to discover their contents. <b><i>Results:</i></b> In the first part of analysis, the top 100 cited articles were all published in 17 journals, with 26 articles published in<i> Neurology</i>. The most frequent topic subject of neurodegeneration appeared in 40 articles. The second part of the analysis revealed that the top 100 cited articles were also all published in 17 journals, with 30 articles published in <i>New England Journal of Medicine</i>. In contrast to the first part of the analysis, stroke was the most frequent topic subject (in 38 articles). <b><i>Conclusions:</i></b> Our bibliometric analysis has yielded 2 detailed lists of the top 100 cited articles that were listed separately using different methods. This approach can provide information about the trends and academic achievements in the field of clinical neurology.
DOI: 10.6084/m9.figshare.4564912.v1
title: Supplementary Material for: Initiation and Cessation Timing of Renal Replacement Therapy in Patients with Type 1 Cardiorenal Syndrome: An Observational Study

description: <b><i>Background/Aims:</i></b> Renal replacement therapy (RRT) is a rescue therapy for patients with type 1 cardiorenal syndrome (CRS) with poor prognoses. However, the optimal timing for initiation and cessation of RRT remains controversial. The purpose of this study was to determine the optimal timing of initiation and cessation of RRT for patients with type 1 CRS. <b><i>Methods:</i></b> In this retrospective analysis, patients with refractory type 1 CRS receiving RRT were divided into 3 groups according to weaning from RRT and death within 90 days. Baseline characteristics, underlying heart disease, comorbidities, drug use before RRT, indicators of RRT initiation, and prognosis were compared between the 3 groups. <b><i>Results:</i></b> Fifty-two patients were enrolled, which included 27 males and 25 females with a mean age of 70.7 ± 16.1 years and a 90-day mortality rate of 65.4%. The mean urine output before RRT initiation was 800 mL/ 24 h in the RRT-independent group, 650 mL/24 h in the RRT-dependent group, and 345 mL/ 24 h in the death group (<i>p</i> = 0.021). Additionally, there were obvious differences in fluid balance between the 3 groups (167, 250, and 1,270 mL, respectively, <i>p</i> = 0.016). Patients could be successfully weaned from RRT when urine output was &gt;880 mL and fluid balance volume was &lt;150 mL. <b><i>Conclusion:</i></b> The mean fluid balance of survivors was remarkably less than that of the death group at RRT initiation. RRT termination can be considered when urine output is &gt;880 mL/24 h and volume balance is &lt;150 mL/24 h.
DOI: 10.6084/m9.figshare.4567999.v21
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.
DOI: 10.6084/m9.figshare.4567999
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.
DOI: 10.6084/m9.figshare.4564831
title: RTPCR_ekdr_Ykro_Chouaibou.txt

description: The current table represents the crude results obtained from amplification of DNA field samples for east kdr mutation detection in Yamoussoukro population of malaria vectors.<br>The tables stand for susceptibility test results with deltamethrin, bendiocarb, malathion and DDT.
DOI: 10.6084/m9.figshare.4567999.v23
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.
DOI: 10.6084/m9.figshare.4567999.v24
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a Type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this article, an alternative TOST based on the effect size is demonstrated to maintain the desired Type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the article. Supplementary materials for this article are avalilable online.
DOI: 10.6084/m9.figshare.4564795
title: Integrative taxonomy reveals too extensive lumping and a new species in the moss genus <i>Amphidium</i> (Bryophyta)

description: An integrative taxonomic approach, including molecular phylogenetic reconstructions based on plastid <i>rps4-trnF</i> and nuclear ITS sequences, statistical analysis of morphological-anatomical characters, and classical taxonomy, indicates that the reduction of 13 <i>Amphidium</i> species to three in a recent morphological revision represents a case of too extensive lumping. Instead, six <i>Amphidium</i> species can be distinguished based on molecular and morphological data, the widespread <i>Amphidium lapponicum</i>, <i>A. mougeotii</i>, and <i>A. tortuosum</i>, as well as the Macaronesian endemic <i>A. curvipes</i>, the North American endemic <i>A. californicum</i>, and a newly discovered species from Central Asia (southern Siberia and northern Mongolia), <i>A. asiaticum</i> sp. nov. Diagnostic morphological characters for all six species are discussed. The present data confirm that species diversity of <i>Amphidium</i> is highest in the Holarctic, where all six species occur.
DOI: 10.6084/m9.figshare.4564795.v1
title: Integrative taxonomy reveals too extensive lumping and a new species in the moss genus <i>Amphidium</i> (Bryophyta)

description: An integrative taxonomic approach, including molecular phylogenetic reconstructions based on plastid <i>rps4-trnF</i> and nuclear ITS sequences, statistical analysis of morphological-anatomical characters, and classical taxonomy, indicates that the reduction of 13 <i>Amphidium</i> species to three in a recent morphological revision represents a case of too extensive lumping. Instead, six <i>Amphidium</i> species can be distinguished based on molecular and morphological data, the widespread <i>Amphidium lapponicum</i>, <i>A. mougeotii</i>, and <i>A. tortuosum</i>, as well as the Macaronesian endemic <i>A. curvipes</i>, the North American endemic <i>A. californicum</i>, and a newly discovered species from Central Asia (southern Siberia and northern Mongolia), <i>A. asiaticum</i> sp. nov. Diagnostic morphological characters for all six species are discussed. The present data confirm that species diversity of <i>Amphidium</i> is highest in the Holarctic, where all six species occur.
DOI: 10.6084/m9.figshare.4567999.v25
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.
DOI: 10.6084/m9.figshare.4567999.v26
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a Type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this article, an alternative TOST based on the effect size is demonstrated to maintain the desired Type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the article. Supplementary materials for this article are avalilable online.
DOI: 10.6084/m9.figshare.4567999.v27
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.
DOI: 10.6084/m9.figshare.4567999.v28
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a Type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this article, an alternative TOST based on the effect size is demonstrated to maintain the desired Type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the article. Supplementary materials for this article are avalilable online.
DOI: 10.6084/m9.figshare.4567999.v29
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.
DOI: 10.6084/m9.figshare.4564705
title: Table S2. Characteristics of included studies from Low statistical power in biomedical science: a review of three human research domains

description: Studies with low statistical power increase the likelihood that a statistically significant finding represents a false positive result. We conducted a review of meta-analyses of studies investigating the association of biological, environmental or cognitive parameters with neurological, psychiatric and somatic diseases, excluding treatment studies, in order to estimate the average statistical power across these domains. Taking the effect size indicated by a meta-analysis as the best estimate of the likely true effect size, and assuming a threshold for declaring statistical significance of 5%, we found that approximately 50% of studies have statistical power in the 0–10% or 11–20% range, well below the minimum of 80% that is often considered conventional. Studies with low statistical power appear to be common in the biomedical sciences, at least in the specific subject areas captured by our search strategy. However, we also observe evidence that this depends in part on research methodology, with candidate gene studies showing very low average power and studies using cognitive/behavioural measures showing high average power. This warrants further investigation.
DOI: 10.6084/m9.figshare.4564705.v2
title: Table S2. Characteristics of included studies from Low statistical power in biomedical science: a review of three human research domains

description: Studies with low statistical power increase the likelihood that a statistically significant finding represents a false positive result. We conducted a review of meta-analyses of studies investigating the association of biological, environmental or cognitive parameters with neurological, psychiatric and somatic diseases, excluding treatment studies, in order to estimate the average statistical power across these domains. Taking the effect size indicated by a meta-analysis as the best estimate of the likely true effect size, and assuming a threshold for declaring statistical significance of 5%, we found that approximately 50% of studies have statistical power in the 0–10% or 11–20% range, well below the minimum of 80% that is often considered conventional. Studies with low statistical power appear to be common in the biomedical sciences, at least in the specific subject areas captured by our search strategy. However, we also observe evidence that this depends in part on research methodology, with candidate gene studies showing very low average power and studies using cognitive/behavioural measures showing high average power. This warrants further investigation.
DOI: 10.6084/m9.figshare.4567999.v30
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a Type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this article, an alternative TOST based on the effect size is demonstrated to maintain the desired Type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the article. Supplementary materials for this article are avalilable online.
DOI: 10.6084/m9.figshare.4564705.v1
title: Table S2. Characteristics of included studies from Low statistical power in biomedical science: a review of three human research domains

description: Studies with low statistical power increase the likelihood that a statistically significant finding represents a false positive result. We conducted a review of meta-analyses of studies investigating the association of biological, environmental or cognitive parameters with neurological, psychiatric and somatic diseases, excluding treatment studies, in order to estimate the average statistical power across these domains. Taking the effect size indicated by a meta-analysis as the best estimate of the likely true effect size, and assuming a threshold for declaring statistical significance of 5%, we found that approximately 50% of studies have statistical power in the 0–10% or 11–20% range, well below the minimum of 80% that is often considered conventional. Studies with low statistical power appear to be common in the biomedical sciences, at least in the specific subject areas captured by our search strategy. However, we also observe evidence that this depends in part on research methodology, with candidate gene studies showing very low average power and studies using cognitive/behavioural measures showing high average power. This warrants further investigation.
DOI: 10.6084/m9.figshare.4567999.v31
title: Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

description: Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.